NeuroNOS
Developing a Novel Treatment for Autism
Company Overview
Snapshot
Founded in March 2024 by Haitham Amal, NeuroNOS operates with 1–10 employees. The company was acquired by XTL Biopharmaceuticals in January 2026, marking a significant milestone in its development of therapies for neurological disorders.
Business overview
NeuroNOS is a biotechnology company specializing in mechanism-based therapies for neurological disorders, with an initial focus on autism spectrum disorder (ASD). The company's core technology targets the dysregulation of neuronal nitric oxide (nNOS), identified as a key biological driver of ASD affecting synaptic function, oxidative stress, and brain metabolism. NeuroNOS is advancing a selective nNOS-targeted small molecule, supported by preclinical data, and operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
The acquisition of NeuroNOS by XTL Biopharmaceuticals in January 2026 signals a strategic entry into the autism market, leveraging NeuroNOS's novel treatment approach. This move validates NeuroNOS's scientific leadership and preclinical progress, indicating a strong potential for its nNOS-targeted small molecule to address a significant unmet medical need in neurological disorders.
Log in to access full profile ›Company Intelligence Q&A
- What is NeuroNOS's primary focus?
- NeuroNOS is focused on developing mechanism-based therapies for neurological disorders, with an initial emphasis on autism spectrum disorder (ASD).
- Who founded NeuroNOS?
- NeuroNOS was co-founded by Haitham Amal.
- When was NeuroNOS acquired?
- NeuroNOS was acquired by XTL Biopharmaceuticals in January 2026.
- What is the scientific basis of NeuroNOS's approach?
- NeuroNOS's approach is based on research identifying dysregulation of neuronal nitric oxide (nNOS) as a key biological driver of ASD, affecting synaptic function, oxidative stress, and brain metabolism.
- What is the current status of NeuroNOS's lead therapeutic candidate?
- NeuroNOS is advancing a selective nNOS-targeted small molecule, supported by preclinical data, and is preparing for first-in-human clinical trials.